Boston Scientific Guides Q4 Well Below Consensus, Warns 2027 Is the Trough
BSX is trading near its 52-week low of $39.57 (6.4% above the low).
Summary
Boston Scientific guided fourth-quarter adjusted EPS to 77-79 cents against an 84-cent consensus and Q4 sales to $5.127-$5.233 billion versus $5.404 billion expected — a wide miss on both lines. Q3 sales came in at $5.138 billion, up 1.5%, above the $5.046 billion consensus but below management's own $5.217-$5.318 billion guide; adjusted EPS of 73 cents beat the 72-cent consensus but fell short of the 80-82 cent internal guide. CEO Mike Mahoney said the EP and WATCHMAN franchises are now dragging total company growth, and told investors 2027 will be the trough — with sales and adjusted EPS challenged to grow next year excluding the pending Penumbra acquisition, plus additional China price headwinds. The stock is down 11.56% at $39.85, a new 52-week low. This extends the damage from the August 25 cyberattack, which management said would materially hit Q3 and full-year 2026 results and cut sales growth by 300 basis points. Management points to restructuring and new product launches to exit the cycle in 2027 and return to high performance in 2028, but the near-term numbers are what matter now.
At the time of this announcement, BSX was trading at $42.11 on NYSE in the Life Sciences sector, with a market capitalization of approximately $61B. The 52-week trading range was $39.57 to $105.65. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Benzinga.